China Europe Fund’s Ge Lan Adds GenScript Bio in Q3, Stays Bullish on Innovative Drugs

A high-conviction manager adding to a single biotech name is a signal worth noting, but the read-across is limited: the disclosure covers one fund family's positioning, not a broader institutional shift. The detail that matters more is structural — a co-manager added to the larger healthcare vehicle months before this filing, which makes it harder to attribute the move to one person's conviction alone. Whether the innovative-drugs thesis holds through the next reporting cycle, and whether the added stake is sustained rather than a one-quarter trade, is the open question.